Design, synthesis, radiolabeling and in Vitro and in Vivo characterization of tumor-antigen- And antibody-derived peptides for the detection of breast cancer

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1399-1410

  Okarvi, Subhani M ^a   Jammaz, Ibrahim A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Biodistribution; Breast cancer; Radiolabeling; Tumor antigen peptides; Tumor cell binding

Indexed keywords

CANCER ANTIBODY; HISTIDINE; MUCIN 1; TECHNETIUM 99M; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MUSCLE LEVEL; DRUG STABILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; GENE OVEREXPRESSION; HEPATOBILIARY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG DESIGN; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUCIN-1; ORGANOTECHNETIUM COMPOUNDS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 64949131893     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Knutson KL, Schiffman K and Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484, 2001.
2. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
3. Knutson KL, Schiffman K, Cheever MA and Disis ML: Immunization of cancer patients with a HER-2/neu. HLA-A2 peptide, p. 369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8: 1014-1018, 2002.
4. Apostolopoulos V, Matsoukas J, Plebanski M and Mavromoustakos T: Applications of peptide mimetics in cancer. Curr Med Chem 9: 411-420,2002.
5. Moore A, Medarova Z, Potthast A and Dai G: In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 64: 1821-1827, 2004.
6. Miiller S and Hanisch F-G: Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. J Biol Chem 277: 26103-26112, 2002.
7. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ and Kumar R: HER2 regulation of peroxisome proliferator-activated receptor y (PPARy) expression and sensitivity of breast cancer cells to PPARy ligand therapy. Clin Cancer Res 9: 3198-3203, 2003.
8. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
9. Natali PG, Nicotra MR, Bigotti A, Ventura I, Slamon DJ, Fendly BM and Ullrich A: Expression of the pl85 encoded by herl oncogene in normal and transformed human tissues. Int J Cancer 45: 457-461, 1990.
10. Olafsen T, Tan GJ, Cheung C-W, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF and Wu AM: Characterization of engineered anti-pl85HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17: 315-323, 2004.
11. 3) sequence. Eur J Nucl Med Mol Imaging 34: 722-733, 2007.
12. Pero SC, Shukla GS, Armstrong AL, Peterson D, Fuller SP, Godin K, Kingsley-Richards SL, Weaver DL, Bond J and Krag DN: Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer 111: 951-960, 2004.
13. Behr T M, Béhé M and Wörmann B: Trastuzumab and breast cancer. N Engl J Med 345: 995-996, 2001.
14. l11In-DTPA-trastuzumab. Br J Pharmacol 143: 99-106, 2004.
15. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
16. l11In-Benzyl-DTPA-ZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47: 846-853,2006.
17. De Santes K, Slamon D, Anderson S K, Shepard M, Fendly B, Maneval D and Press D: Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 52: 1916-1923, 1992.
18. Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao X-G, Slade SK, Affleck DJ and Bast RC Jr: Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 26: 781-790, 1999.
19. l11In- trastuzumab (Herceptin™) Fab fragments. Nucl Med Biol 32: 51-58,2005.
20. Tsai SW, Sun YY, Williams LE, Raubitschek AA, Wu AM and Shively JE: Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjugate Chem 11: 327-334, 2000.
21. Britz-Cunningham SH and Adelstein SJ: Molecular targeting with radionuclides: State of science. J Nucl Med 44: 1945-1961, 2003.
22. HER/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 18: 194-198,2000.
23. Okarvi SM: Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancers. Cancer Treat Rev 34: 13-26, 2008.
24. 3) with different S-protective groups. J Labelled Cpd Radiopharm 39: 853-874, 1997.
25. Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM and Ioannides CG: Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6: 4192-4200, 2000.
26. Correa I and Plunkett T: Update on HER-2 as a target for cancer therapy. HER2/neu peptides as tumour vaccines for T-cell recognition. Breast Cancer Res 3: 399-403, 2001.
27. + tumors. Cancer Res 58: 4902-4908, 1998.
28. Agrawal B, Reddish MA, Christian B, VanHeele A, Tang L, Koganty RR and Longenecker BM: The anti-MUCl monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class 1 associated amino acid sequences. Cancer Res 58: 5151-5156, 1998.
29. Okarvi SM: Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent. J Peptide Res 63: 460-468, 2004.
30. Sivolapenko GB, Douli V, Pectasides D, Skarlos D, Sirmalis G, Hussain R, Cook J, Courtenay-Luck NS, Merkouri E, Konstantinides K and Epenetos AA: Breast cancer imaging with radiolabeled peptide from complementarity-determining region of antitumour antibody. Lancet 346: 1662-1666,1995.
31. Grant GA: Synthetic Peptides. New York, Oxford University Press, 2002.
32. 3 and biodistribution of by-products. Appl Radiat Isot 39: 121-129, 1988.
33. Fukuoka M, Kiyohara T, Kobayashi T, Kojima A, Tanaka A and Kubodera A: Synthesis and preclinical evaluation of technetium-99m-labeled hippurate analogues. Nucl Med Biol 22: 181-191, 1995.
34. Okarvi SM and Jammaz IA: Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radio 21: 49-60, 2006.
35. 11C]DASB for measuring endogenous serotonin with PET: binding studies. Nucl Med Biol 32: 129-136, 2005.
36. l1In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J Nucl Med 43: 1650-1656, 2002.
37. Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW and Waldmann TA: Immuno-conjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 92: 1573-1581, 2000.
38. Guide for the Care and Use of Laboratory Animals. Washington, D.C., National Academy Press: 1996.
39. 99mTc-labelled peptides. Q J Nucl Med 46: 195-205, 2002.
40. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu H-L, Munishkin A, Beauheim C, Harvey S, Ethier SP and Johnson P H: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61: 5168-5178,2001.
41. Mullin AE and Jean-Claude B: HER2/new oncogene and sensitivity to the DNA-interactive drug Doxorubicin. McGill J Med 4: 9-15, 1998.
42. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE: CXCL-12/stromal cell-derived factor-la transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65: 6493-6497,2005.
43. Ueno NT, Yu D and Hung M-C: Chemosensitization of HER- 2/new-overexpressing breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 75: 953-960, 1997.
44. Walsh MD, Luckie SM, Cummings MC, Antalis TM and McGuckin MA: Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast cancer Res Treat 58: 255-266, 2000.
45. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ and Morris JC: In vivo radionuclide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 11: 1483-1489, 2005.
46. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J and Eberle AN: Characterization of receptors for a-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 49: 6352-6358,1989.